0V0.F VIMIAN GROUP AB

Healthcare Biotechnology Frankfurt Exchange
3.74 EUR
Close of Nov 11, 2026
2.25 3.80
Market cap
EUR 1.97B
P/E
53.3x
P/B
2.63x
ROE
4.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0V0.F undervalued?

Graham number
Price3.74
Graham value1.50
Premium149.7%

0V0.F trades 149.7% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VIMIAN GROUP AB fundamental analysis

No fundamental analysis for VIMIAN GROUP AB yet.

VIMIAN GROUP AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VIMIAN GROUP AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through four segments: Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applicati…

Full company profile